- Home
- LPRO vs EDIT Comparison
LPRO vs EDIT Comparison
Compare LPRO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | EDIT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 432.8M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LPRO | EDIT |
|---|---|---|
| Price | $3.14 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.58 | ★ $5.30 |
| AVG Volume (30 Days) | ★ 5.9M | 2.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.46 | 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $10.58 | N/A |
| Revenue Next Year | $14.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $1.18 | $1.66 |
| 52 Week High | $3.14 | $4.54 |
Technical Indicators
Market Signals| Indicator | LPRO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 71.45 | 40.83 |
| Support Level | $2.00 | $2.26 |
| Resistance Level | N/A | $3.27 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 100.00 | 2.77 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is a provider of lending enablement and risk analytics to credit unions, regional banks, finance companies and the captive finance companies of automakers (OEM captive finance companies). Through its flagship product, LPP, its customers, collectively referred to herein as automotive lenders or lenders, make automotive consumer loans to underserved near-prime and non-prime borrowers by harnessing its risk-based interest rate pricing models, powered by its proprietary data and real-time underwriting of automotive loan default insurance coverage from insurers.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.